Latest / My Life On GLP1 / S13.E6: My Life On GLP1 - Geographic Use (US, UK, Canada): Where GLP1 Meds Are Exploding
Transcript
- 0:03SPEAKER_00: Welcome to My Life on a GLP 1.
- 0:06SPEAKER_00: I'm your host Scott Johnson, and as always, I'm joined by my brilliant co-host Sarah.
- 0:13SPEAKER_00: Today we're diving into something fascinating that affects every single person listening to this show.
- 0:20SPEAKER_00: It is a lesson in global geography.
- 0:23SPEAKER_00: We dug into the data that shows how where you live literally can influence your access to GLP1 medications.
- 0:31SPEAKER_01: Thanks, Scott.
- 0:31SPEAKER_01: And wow, when we started digging into the geographic data, it was honestly shocking.
- 0:36SPEAKER_01: We're not just talking small differences here, we're talking about dramatic regional divides that can make or break someone's treatment journey.
- 0:43SPEAKER_00: Right.
- 0:44SPEAKER_00: So let's start with the United States, where the pattern is crystal clear.
- 0:49SPEAKER_00: The Northeast is absolutely dominating GLP 1 adoption rates.
- 0:54SPEAKER_00: We're talking states like Massachusetts, Connecticut, New York.
- 0:58SPEAKER_01: Mm-hmm.
- 0:59SPEAKER_01: That is kind of interesting, but not all that surprising.
- 1:02SPEAKER_00: These areas have adoption rates that are sometimes double what we see in southern states.
- 1:07SPEAKER_00: And it's not just about population density.
- 1:10SPEAKER_00: There's something deeper happening here.
- 1:12SPEAKER_01: It really comes down to insurance coverage, doesn't it?
- 1:15SPEAKER_01: Like I was talking to someone from Alabama last week and their insurance flat out refuses to cover Ozempic or Manjaro unless you have diabetes.
- 1:23SPEAKER_01: But meanwhile, someone in Vermont gets covered for weight management with minimal pushback.
- 1:28SPEAKER_00: That's such a perfect example.
- 1:30SPEAKER_00: And it gets even more complicated when you factor in state Medicaid policies.
- 1:36SPEAKER_00: Some states are progressive about obesity treatment.
- 1:39SPEAKER_00: Others not so much.
- 1:42SPEAKER_01: Right now, if we hop across the Atlantic to the UK, they have their own version of this geographic lottery, and they literally call it that the postcode lottery.
- 1:51SPEAKER_00: Oh, the NHS system is wild.
- 1:53SPEAKER_00: Depending on which clinical commissioning group you fall under, your access to GLP ones can be completely different from someone living just a few miles away.
- 2:03SPEAKER_01: Exactly.
- 2:04SPEAKER_01: And some areas have these incredibly strict BMI requirements or require you to fail multiple other treatments first.
- 2:10SPEAKER_01: It's like they're playing different games with the same rule book.
- 2:13SPEAKER_00: It is worth noting that Scotland, Wales, and Northern Ireland operate their own health systems separate from NHS England.
- 2:22SPEAKER_00: Coverage decisions and implementation timelines differ, adding another layer of complexity to UK access patterns.
- 2:30SPEAKER_00: Generally speaking, Scotland has been somewhat more progressive in commissioning weight management services, while Wales and Northern Ireland have faced even greater capacity constraints than England.
- 2:43SPEAKER_01: Private clinics and online telemedicine services now offer consultations and prescriptions.
- 2:48SPEAKER_01: However, these patients must pay out of pocket for both the medical visit and the medication itself.
- 2:53SPEAKER_01: This private market serves people with means while those dependent on NHS care wait.
- 2:59SPEAKER_01: It is precisely the kind of inequality that the NHS was designed to prevent.
- 3:05SPEAKER_00: But then you look at Canada, and it's a completely different story.
- 3:09SPEAKER_00: The growth has been absolutely explosive across all provinces, like uniformly incredible adoption rates.
- 3:17SPEAKER_01: Yeah, Ontario, British Columbia, Alberta, everyone's seeing similar patterns.
- 3:21SPEAKER_01: And here's what's really exciting: Canada is about to become the first major market with biosimilar GLP ones.
- 3:28SPEAKER_00: That's huge.
- 3:29SPEAKER_00: Generic versions could completely change the accessibility game.
- 3:33SPEAKER_00: Imagine getting the same medication for a fraction of the cost.
- 3:38SPEAKER_01: Totally.
- 3:39SPEAKER_01: But let's talk about something that affects everyone, regardless of country, urban versus rural access.
- 3:45SPEAKER_01: This is where things get really challenging.
- 3:48SPEAKER_00: Oh man, rural access is tough.
- 3:50SPEAKER_00: You've got fewer endocrinologists, longer wait times, and pharmacies that might not even stock these medications regularly because they're so expensive to keep on hand.
- 4:01SPEAKER_01: Right.
- 4:02SPEAKER_01: And then there are the supply shortages.
- 4:03SPEAKER_01: I mean, we've all been there.
- 4:05SPEAKER_01: You show up to your pharmacy and they're like, sorry, we don't have your dose this month.
- 4:09SPEAKER_00: It's so frustrating.
- 4:10SPEAKER_00: And urban areas tend to recover from shortages faster because they have more pharmacy chains and better distribution networks.
- 4:18SPEAKER_00: Rural folks are often left scrambling.
- 4:21SPEAKER_01: I actually heard from someone in Montana who drives three hours round trip just to get to a pharmacy that reliably stocks their medication.
- 4:29SPEAKER_01: Three hours.
- 4:30SPEAKER_00: That's heartbreaking, but not uncommon.
- 4:33SPEAKER_00: And you know what's interesting?
- 4:35SPEAKER_00: Some people are getting creative, forming carpools to pharmacies and ordering from different states.
- 4:42SPEAKER_01: Yeah, the lengths people go to for treatment access really highlights how broken some of these systems are, but here's what gives me hope.
- 4:49SPEAKER_01: Awareness is growing.
- 4:51SPEAKER_01: More insurance companies are starting to cover these medications, and policy makers are finally paying attention.
- 4:57SPEAKER_00: Absolutely.
- 4:58SPEAKER_00: And as more data comes out showing the long-term health benefits, not just weight loss, but cardiovascular protection, kidney benefits, it becomes harder to justify these geographic disparities.
- 5:11SPEAKER_01: Exactly.
- 5:12SPEAKER_01: Scott, what's your advice for listeners who are dealing with access challenges based on where they live?
- 5:17SPEAKER_00: Great question.
- 5:18SPEAKER_00: First, don't give up.
- 5:20SPEAKER_00: Work with your doctor to appeal insurance denials, look into patient assistance programs, and consider telemedicine if local specialists are limited.
- 5:30SPEAKER_00: The landscape is changing fast, so what's not possible today might be next month.
- 5:36SPEAKER_01: Perfect advice, and remember you're not alone in this journey.
- 5:39SPEAKER_01: Connect with others in your area, share resources, and keep advocating for better access.
- 5:44SPEAKER_00: And if you find yourself making seven phone calls to fill a prescription or driving across state lines to find a pharmacy with stock, know that you are not alone.
- 5:55SPEAKER_00: Millions of people across North America and the UK are navigating the same challenges, and their collective experiences slowly but surely pushing systems to improve access and equity.
- 6:09SPEAKER_01: Understanding these patterns is the first step toward addressing them.
- 6:12SPEAKER_01: Patients can advocate more effectively when they understand the systemic barriers they face.
- 6:17SPEAKER_01: Now I know you have some staggering final statistics to share, but before you do, I ask each of you, our listeners, to take a moment, leave us a comment, or give a five-star rating wherever you stream your podcasts.
- 6:29SPEAKER_01: I personally thank you in advance for doing this.
- 6:32SPEAKER_01: And don't forget to check out Scott's website at mylifeonglp one.com for the latest news, tips, and tricks.
- 6:39SPEAKER_01: You can also drop us an email at Scott at MyLifeOnGLP1.com or Sarah with an H at mylife on GLP1.com.
- 6:48SPEAKER_01: Now tell us, Scott, what final numbers do you want to share with us today?
- 6:52SPEAKER_00: Multiple nationally representative surveys conducted in 2024 and early 2025 tell us that about 12% of US adults have used a GLP one medication, and approximately 6% are current users.
- 7:10SPEAKER_00: These numbers represent remarkable market penetration for medications that only became widely known to the public in the past few years.
- 7:20SPEAKER_00: If six percent of American adults are current users, that translates to approximately fifteen million people taking these medications at present.
- 7:30SPEAKER_00: So whether you are covered by insurance or paying privately, know that you are a part of a community of fifteen million who all support each other.
- 7:39SPEAKER_00: That's all for today's episode.
- 7:41SPEAKER_00: Thanks for joining us.
- 7:43SPEAKER_00: I'm Scott Johnson, along with Sarah, reminding you that geography might influence your access, but it doesn't define your possibilities.
- 7:52SPEAKER_00: Stay healthy, strong, and supportive, and always love your journey.